These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 16946524

  • 21. Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation.
    González-Pérez V, Connolly EA, Bridges AS, Wienkers LC, Paine MF.
    Drug Metab Dispos; 2012 Nov; 40(11):2136-42. PubMed ID: 22896727
    [Abstract] [Full Text] [Related]

  • 22. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
    Thijssen HH, Flinois JP, Beaune PH.
    Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
    [Abstract] [Full Text] [Related]

  • 23. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
    Wester MR, Lasker JM, Johnson EF, Raucy JL.
    Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
    [Abstract] [Full Text] [Related]

  • 24. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
    Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M.
    Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM, Wester MR, Aramsombatdee E, Raucy JL.
    Arch Biochem Biophys; 1998 May 01; 353(1):16-28. PubMed ID: 9578596
    [Abstract] [Full Text] [Related]

  • 28. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
    Voorman RL, Payne NA, Wienkers LC, Hauer MJ, Sanders PE.
    Drug Metab Dispos; 2001 Jan 01; 29(1):41-7. PubMed ID: 11124228
    [Abstract] [Full Text] [Related]

  • 29. Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes.
    Miyazawa M, Shindo M, Shimada T.
    Drug Metab Dispos; 2002 May 01; 30(5):602-7. PubMed ID: 11950794
    [Abstract] [Full Text] [Related]

  • 30. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
    Hanatani T, Fukuda T, Ikeda M, Imaoka S, Hiroi T, Funae Y, Azuma J.
    Pharmacogenomics J; 2001 May 01; 1(4):288-92. PubMed ID: 11908770
    [Abstract] [Full Text] [Related]

  • 31. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.
    Brantley SJ, Oberlies NH, Kroll DJ, Paine MF.
    J Pharmacol Exp Ther; 2010 Mar 01; 332(3):1081-7. PubMed ID: 19934397
    [Abstract] [Full Text] [Related]

  • 32. CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver.
    Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S.
    Drug Metab Dispos; 2008 Dec 01; 36(12):2429-33. PubMed ID: 18784266
    [Abstract] [Full Text] [Related]

  • 33. 7-Hydroxylation of warfarin is strongly inhibited by sesamin, but not by episesamin, caffeic and ferulic acids in human hepatic microsomes.
    Pilipenko N, Rasmussen MK, Doran O, Zamaratskaia G.
    Food Chem Toxicol; 2018 Mar 01; 113():14-18. PubMed ID: 29353070
    [Abstract] [Full Text] [Related]

  • 34. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X, Wang JS, Backman JT, Kivistö KT, Neuvonen PJ.
    Drug Metab Dispos; 2001 Nov 01; 29(11):1359-61. PubMed ID: 11602509
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.
    Kim KA, Park JY.
    Drug Metab Dispos; 2003 Sep 01; 31(9):1090-2. PubMed ID: 12920163
    [Abstract] [Full Text] [Related]

  • 37. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers.
    Yamazaki H, Shimada T.
    Biochem Pharmacol; 1997 Dec 01; 54(11):1195-203. PubMed ID: 9416970
    [Abstract] [Full Text] [Related]

  • 38. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H.
    Clin Pharmacol Ther; 1998 May 01; 63(5):519-28. PubMed ID: 9630825
    [Abstract] [Full Text] [Related]

  • 39. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
    Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G.
    Eur J Clin Pharmacol; 2004 May 01; 60(3):173-82. PubMed ID: 15054565
    [Abstract] [Full Text] [Related]

  • 40. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
    Yamazaki H, Shimada T.
    Drug Metab Dispos; 1998 Nov 01; 26(11):1053-7. PubMed ID: 9806945
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.